Sign inJoin waitlistJoin the waitlist

Hossein Sadrzadeh

Hematology/Oncology · Lahey Clinic

Credentials: · · · · ·

History

Lahey Clinic
Present

Hematology and Medical Oncology
Boston University Medical Center
2020–2023
Geriatric Medicine
Boston University Medical Center
2018–2019
Internal Medicine
Capital Health Regional Medical Center
Chief Resident
2016–2017
Mazandaran University of Medical Sciences
2010–2014

Research

Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response
Blood · 2012 · 100 citations
Presentation and outcomes among patients with isolated myeloid sarcoma: a Surveillance, Epidemiology, and End Results database analysis
Leukemia & lymphoma/Leukemia and lymphoma · 2015 · 74 citations
Epidemiology of pheochromocytoma and paraganglioma: population-based cohort study
European Journal of Endocrinology · 2021 · 71 citations

Amir Fathi
19 papers · 1 as a fellow
Karen Ballen
8 papers
Andrew Brunner
7 papers · 5 as a fellow
EA
Eyal Attar
7 papers
PA
Philip Amrein
7 papers
Robert Hasserjian
5 papers
MF
Matthew Frigault
4 papers
Benjamin Drapkin
3 papers · 3 as a fellow
SA
Samuel Agresta
3 papers
SM
Steven Mcafee
3 papers
Anthony Iafrate
2 papers
Ashley Perry
2 papers

Clinical trials

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2029
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2027
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2027